Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen

Background: Nusinersen is an antisense-oligonucleotide (ASO) approved for treatment of 5q-spinal muscular atrophy (SMA). Since the drug cannot cross the blood-brain barrier (BBB), it must be administered into the cerebrospinal fluid (CSF) space repeatedly by lumbar puncture. However, little is known...

詳細記述

保存先:
書誌詳細
出版年:Front Neurol
主要な著者: Wurster, Claudia D., Koch, Jan C., Cordts, Isabell, Dreyhaupt, Jens, Otto, Markus, Uzelac, Zeljko, Witzel, Simon, Winter, Benedikt, Kocak, Tugrul, Schocke, Michael, Weydt, Patrick, Wollinsky, Kurt, Ludolph, Albert C., Deschauer, Marcus, Lingor, Paul, Tumani, Hayrettin, Hermann, Andreas, Günther, René
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2019
主題:
Neurology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854024/
https://ncbi.nlm.nih.gov/pubmed/31787927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.01179
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料